Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients? Michael A. Marchetti, MD, Edmund K. Bartlett,

Slides:

Advertisements

Similar presentations

Use of the diagonal mattress suture to prevent dog-ear formation

Advertisements

Yin-Shuo Chang, MD, Yu-Chen Huang, MD

Clavi syphilitici–an unusual presentation of syphilis

Analysis of US dermatology physician assistant density

Kavitha K. Reddy, MD, Jeremy A. Brauer, MD, Roy G. Geronemus, MD

Analysis of US dermatology physician assistant density

A girl with a solitary red bulla

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD

Focal nail dystrophy in a cutaneous nerve distribution after trauma

Array of cutaneous adverse effects associated with sorafenib

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced.

Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression Luigi Rusciani, MD, Ilaria Proietti, MD, Antonio Rusciani,

Diameter of dysplastic nevi is a more robust biomarker of increased melanoma risk than degree of histologic dysplasia: A case-control study Michael Y.

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Rachel L. Kyllo, BS, Mary Kendall Parker, MD, Ilana Rosman, MD, Amy C

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Methotrexate treatment in patients with a history of cutaneous melanoma and the risk of a consecutive primary melanoma: A national retrospective registry-based.

Heterogeneous spectrum of acral melanoma: A clinicoprognostic study of 213 acral melanomas according to tumor site Hye Rim Moon, MD, Hyun Ji Kang, MD,

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Reply to: “A note on normality”

The applicability and prognostic value of the TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases Alan S. Boyd, MD, Bashar Shakhtour,

Lip edema Journal of the American Academy of Dermatology

Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma Pedram Gerami, MD, Zuxu Yao, PhD, David Polsky, MD, PhD, Burkhard.

Pooja H. Rambhia, BA, Ivan J. Stojanov, DMD, Joshua Arbesman, MD

Hugh Gloster, MD, Chesahna Kindred, MBA

Karen L. Connolly, MD, Rajiv I. Nijhawan, MD, Steven W

Medicaid acceptance among pediatric dermatologists

Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma.

Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes.

Recent dermatology visit is associated with thinner Breslow depth nodular melanomas Erin X. Wei, MD, Lucy Chen, MD, Fangchao Ma, PhD, Jonette Keri, MD,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Modification of the nail psoriasis severity index

Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry Ulrike.

Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal peripheral blood lymphocyte count Simon D.J. Gibbs, MBBS, David.

Tofacitinib therapy for children with severe alopecia areata

Gordon W. Jung, MD, Patricia T. Ting, MSc, MD, Thomas G

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Anh Khoa Pham, BSc, Parisa Ravanfar, MD, MBA, MS

Descriptive survival study of nail melanoma patients treated with functional surgery versus distal amputation Suelen Montagner, MD, Francisco Aparecido.

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Lisa A. Beck, MD, Sarbjit Saini, MD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Orit Kaidar-Person, MD, Ayelet Eran, MD, Gil Bar-Sela, MD

The JAAD adopts the CONSORT statement

Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience Andrew F. Alexis, MD, MPH,

Photosensitive lichenoid drug eruption to capecitabine

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients? Michael A. Marchetti, MD, Edmund K. Bartlett, MD, Stephen W. Dusza, DrPH, Christopher K. Bichakjian, MD Journal of the American Academy of Dermatology Volume 80, Issue 6, Pages e161-e162 (June 2019) DOI: 10.1016/j.jaad.2018.11.063 Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Estimate of the clinical performance of the 31-gene expression profile test with 100 hypothetical patients with T1 (thickness, ≤1 mm) cutaneous melanoma and a 5-year distant metastasis–free survival rate of 95%. *These data assume a 5-year distant metastasis–free survival rate of 95% and 31-gene expression profile test sensitivity and specificity of approximately 20% and approximately 90%, respectively.1 Therefore, there would be 10 class 2 results (9 false positives and 1 true positive) and 90 class 1 results (4 false negatives and 86 true negatives). †As the baseline risk of distant metastasis is approximately 95% and the class 1 risk of distant metastasis is approximately 96%, the negative predictive value of the test is unlikely to benefit patients or alter physician-directed surveillance. Comparable analyses were performed for recurrence-free survival (RFS), which was defined by Gastman et al1 as time from diagnosis to local, regional, or distant recurrence. From the data presented in Supplemental Fig 1 of the article by Gastman et al,1 the sensitivity, specificity, positive predictive value, and negative predictive value of a class 2 score in predicting 5-year RFS among patients with T1 melanomas were 33%, 91%, 20%, and 95%, respectively.1 If the 31-gene expression profile test was applied to 100 hypothetical patients with T1 melanoma and a 5-year RFS rate of 94%,1 there would be 2 true positives, 9 false positives, 4 false negatives, and 85 true negatives; thus, 85% of patients would be unaffected, 13% could be harmed by an incorrect result, and 2% could potentially benefit from a correctly anticipated local, regional, or distant recurrence. Journal of the American Academy of Dermatology 2019 80, e161-e162DOI: (10.1016/j.jaad.2018.11.063) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions